PlainRecalls
FDA Drug Moderate Class II Ongoing

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Reported: January 14, 2026 Initiated: December 18, 2025 #D-0251-2026

Product Description

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Reason for Recall

Presence of particulate matter - Glass like particles.

Details

Recalling Firm
Imprimis NJOF, LLC
Units Affected
314 boxes of 6,280 pre-filled syringes
Distribution
U.S Nationwide
Location
Ledgewood, NJ

Frequently Asked Questions

What product was recalled?
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.. Recalled by Imprimis NJOF, LLC. Units affected: 314 boxes of 6,280 pre-filled syringes.
Why was this product recalled?
Presence of particulate matter - Glass like particles.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 14, 2026. Severity: Moderate. Recall number: D-0251-2026.